Identification of High-Risk Human Papillomavirus DNA, p16, and E6/E7 Oncoproteins in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
27 05 2021
Historique:
received: 09 05 2021
revised: 21 05 2021
accepted: 25 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 28 1 2022
Statut: epublish

Résumé

Human papillomavirus (HPV) was proven to play a significant role in cancer development in the oropharynx. However, its role in the development of laryngeal (LSCC) and hypopharyngeal squamous cell carcinoma (HPSCC) remains to be clarified. High-risk HPV (HR-HPV) viral proteins E6 and E7 are considered to be pertinent to HPV-related carcinogenesis. Hence, our aim was to estimate LSCC and HPSCC for HR-HPV DNA, p16, and E6/E7 oncoprotein status by using molecular virology and immunohistochemistry methods. The prevalence of HPV16 infection was 22/41 (53.7%) and 20/31 (64.5%) for LSCC and HPSCC, accordingly. The majority of HPV16+ tumor samples were stage III or IV. In most samples, the presence of either HPV16 E6 or HPV16 E7 viral protein in dysplastic or tumor cells was confirmed using immunohistochemistry. Our results suggest a high prevalence of HPV16 as a primary HR-HPV type in LSCC and HPSCC. The lack of HPV E6/E7 oncoproteins in some tumor samples may suggest either the absence of viral integration or the presence of other mechanisms of tumorigenesis. The utilization of p16 IHC as a surrogate marker of HR-HPV infection is impractical in LSCC and HPSCC.

Identifiants

pubmed: 34072187
pii: v13061008
doi: 10.3390/v13061008
pmc: PMC8229053
pii:
doi:

Substances chimiques

DNA, Viral 0
E6 protein, Human papillomavirus type 16 0
Oncogene Proteins, Viral 0
Papillomavirus E7 Proteins 0
Repressor Proteins 0
oncogene protein E7, Human papillomavirus type 16 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Lancet Glob Health. 2016 Sep;4(9):e609-16
pubmed: 27470177
Int J Cancer. 2014 May 15;134(10):2366-72
pubmed: 24249631
Cancers (Basel). 2020 Mar 10;12(3):
pubmed: 32164347
Pathogens. 2020 Jun 18;9(6):
pubmed: 32570816
Laryngorhinootologie. 2018 Mar;97(S 01):S48-S113
pubmed: 29905354
J Cancer Res Clin Oncol. 2011 Jan;137(1):173-81
pubmed: 20376678
Semin Diagn Pathol. 2015 Sep;32(5):344-51
pubmed: 25724476
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
Cancer Med. 2019 Apr;8(4):1908-1918
pubmed: 30821126
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
Diagn Microbiol Infect Dis. 2014 Sep;80(1):43-9
pubmed: 24953539
Turk J Emerg Med. 2018 Aug 07;18(3):91-93
pubmed: 30191186
Int J Cancer. 2011 Apr 1;128(7):1596-605
pubmed: 20499310
Acta Otorhinolaryngol Ital. 2014 Oct;34(5):299-309
pubmed: 25709145
Cancer Prev Res (Phila). 2019 Jun;12(6):375-382
pubmed: 31003993
JAMA Oncol. 2017 Feb 1;3(2):169-177
pubmed: 27930766
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16175-80
pubmed: 24046371
Viruses. 2017 Sep 19;9(9):
pubmed: 28925973
Sci Rep. 2020 Nov 10;10(1):19459
pubmed: 33173143
Front Oncol. 2020 Sep 15;10:1751
pubmed: 33042820
Int J Mol Sci. 2018 Jun 08;19(6):
pubmed: 29890655
J Virol Methods. 1995 Feb;51(2-3):305-16
pubmed: 7738151
J Cancer Res Clin Oncol. 2020 Jul;146(7):1677-1692
pubmed: 32372145
Virus Res. 2017 Mar 2;231:83-95
pubmed: 27867028
Oral Oncol. 2014 May;50(5):370-9
pubmed: 24331868
Arch Pathol Lab Med. 2018 May;142(5):559-597
pubmed: 29251996
Otolaryngol Head Neck Surg. 2009 Aug;141(2):276-81
pubmed: 19643265
Exp Ther Med. 2016 Nov;12(5):2965-2973
pubmed: 27882102
J Clin Oncol. 2014 Dec 10;32(35):3930-8
pubmed: 25267748
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Int J Cancer. 2010 Apr 15;126(8):1882-1894
pubmed: 19795456
Eur Arch Otorhinolaryngol. 2018 Jul;275(7):1837-1843
pubmed: 29744637
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Int J Cancer. 2016 Jan 15;138(2):386-95
pubmed: 26239888
Am J Surg Pathol. 2017 May;41(5):607-615
pubmed: 28403015
Br J Cancer. 2019 Apr;120(8):827-833
pubmed: 30890775
Cancer. 2015 Jun 15;121(12):1966-76
pubmed: 25731880
World J Otorhinolaryngol Head Neck Surg. 2020 Mar 06;6(1):66-75
pubmed: 32426706
Head Neck. 2011 Apr;33(4):581-6
pubmed: 20848441
Endocr J. 2019 May 28;66(5):423-430
pubmed: 30814438
Curr Oncol Rep. 2019 Apr 17;21(6):52
pubmed: 30997577
Oral Oncol. 2013 Jan;49(1):79-85
pubmed: 22917550
PLoS Pathog. 2017 Apr 6;13(4):e1006211
pubmed: 28384274
Ann Surg Oncol. 2013 Dec;20 Suppl 3:S450-8
pubmed: 23208131
Cancer Res. 2018 May 1;78(9):2383-2395
pubmed: 29440171
Oral Oncol. 2010 Jul;46(7):492-6
pubmed: 20227331
Exp Oncol. 2020 Mar;42(1):51-59
pubmed: 32231193
Genet Mol Res. 2016 Feb 19;15(1):
pubmed: 26909984
Viruses. 2018 Oct 25;10(11):
pubmed: 30366357
J Clin Oncol. 2016 Apr 20;34(12):1300-8
pubmed: 26712222
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1654-8
pubmed: 7878034
J Cancer. 2018 Jul 30;9(16):2938-2945
pubmed: 30123362
Immunotherapy. 2015;7(6):631-40
pubmed: 26098137
J Clin Oncol. 2013 Dec 20;31(36):4550-9
pubmed: 24248688
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Clin Cancer Res. 2011 Oct 1;17(19):6262-71
pubmed: 21969383
Anticancer Res. 2016 Jun;36(6):3195-8
pubmed: 27272848
Oral Oncol. 2018 Jul;82:108-114
pubmed: 29909884
J Virol. 2004 Nov;78(21):11451-60
pubmed: 15479788
Future Sci OA. 2020 Aug 03;6(9):FSO606
pubmed: 33235805
Cancer Lett. 2012 Oct 1;323(1):88-96
pubmed: 22484467
Br J Cancer. 2015 Feb 3;112(3):580-93
pubmed: 25422909
Trends Microbiol. 2011 Jan;19(1):33-9
pubmed: 21050765
Infect Agent Cancer. 2019 Mar 5;14:8
pubmed: 30873218
Mod Pathol. 2018 Nov;31(11):1645-1652
pubmed: 29925856
Lancet Oncol. 2014 Nov;15(12):1319-31
pubmed: 25439690

Auteurs

Andrejs Lifsics (A)

Department of otolaryngology, Riga Stradiņš University, Pilsoņu 13, LV-1002 Riga, Latvia.

Valerija Groma (V)

Institute of Anatomy and Anthropology, Riga Stradiņš University, Kronvalda blvd 9, LV-1010 Riga, Latvia.

Maksims Cistjakovs (M)

Institute of Microbiology and Virology, Riga Stradiņš University, Rātsupītes 5, LV-1067 Riga, Latvia.

Sandra Skuja (S)

Institute of Anatomy and Anthropology, Riga Stradiņš University, Kronvalda blvd 9, LV-1010 Riga, Latvia.

Renars Deksnis (R)

Department of Head and Neck Surgery, Oncology Centre of Latvia, Riga Eastern University Hospital, Hipokrāta 2, LV-1038 Riga, Latvia.

Modra Murovska (M)

Institute of Microbiology and Virology, Riga Stradiņš University, Rātsupītes 5, LV-1067 Riga, Latvia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH